Investor Presentaiton

1 Do I have cancer? Clinically relevant CRC detection capability achieved by epigenomics assay for screening applications 1,2 GUARDANT™ TM shield 1% Stage IV 0.1% 0.01% 0.001% Stage III Current Epigenomic Detection Limits³ Stage II INVESTOR 20 DAY 23 Detection Limits of Genomic Panels Stage 50X improvement 1. Avanzini et al., Sci Adv 6(50) (2020); CRC Tumor Fractions: https://www.biorxiv.org/content/10.1101/2022.01.17.476508v1.article-info.; Internal Data on File 2 Epigenomic detection limits corresponds to 50%-95% detection probability range established using in silico dilutions of clinical screening-relevant CRC samples at typical 20ng input and 90% specificity. 33 33

View entire presentation